Vaxcyte (PCVX) Enterprise Value (2020 - 2026)

Vaxcyte (PCVX) has reported Enterprise Value for 8 consecutive years, with -$1.7 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Enterprise Value fell 3.91% year-over-year to -$1.7 billion; the TTM figure through Mar 2026 stood at -$1.7 billion (down 3.91% YoY), while the FY2025 annual figure was -$1.6 billion, up 10.66% from the prior year.
• Enterprise Value eased to -$1.7 billion in Q1 2026 per PCVX's latest filing, from -$1.6 billion in the prior quarter.
• Across five years, Enterprise Value topped out at -$334.6 million in Q1 2022 and bottomed at -$2.2 billion in Q3 2024.
• Historically, Enterprise Value has averaged -$1.3 billion across 5 years, with a median of -$1.5 billion in 2024.
• Annual changes were most pronounced in 2022 — Enterprise Value plunged 278.65% — and 2025, when it rose 21.52%.
• Vaxcyte's Enterprise Value stood at -$931.4 million in 2022, then fell by 15.98% to -$1.1 billion in 2023, then sank by 61.74% to -$1.7 billion in 2024, then advanced by 10.66% to -$1.6 billion in 2025, then dropped by 11.29% to -$1.7 billion in 2026.
• Business Quant data shows PCVX's Enterprise Value at -$1.7 billion in Q1 2026, -$1.6 billion in Q4 2025, and -$1.7 billion in Q3 2025.